Introductory Chapter: From Chaos to Cosmos – Toward Precision Medicine in Osteosarcoma

Part of book or chapter of book English OPEN
Honoki, Kanya; Weiss, Kurt Richard;
  • Publisher: InTech
  • References (24)
    24 references, page 1 of 3

    [1] Odes EJ, Randolph-Quinney PS, Steyn M, Throckmorton Z, Smilg JS, Zipfel B, Augustine T, De Beer F, Hoffman JW, Franklin RD, Berger LR. Earliest Hominin Cancer: 1.7-MillionYear-Old Osteosarcoma from Swartkrans Cave, South Africa. South African Journal of Science. 2016;1-5, 112. DOI: 17159/sajs.2016/20150471

    [2] Egas-Bejar D, Anderson PM, Agarwal R, Corrales-Medina F, Devarajan E, Huh WW, Brown RE, Subbiah V. Theranostic Profiling for Actionable Aberrations in Advanced High Risk Osteosarcoma with Aggressive Biology Reveals High Molecular Diversity: The Human Fingerprint Hypothesis. Oncoscience. 2014;12:167-179. PMID:25126591; PMCID:PMC4128257. DOI: 10.18632/oncoscience.21

    [3] Collins FS, Varmus H. A New Initiative on Precision Medicine. The New England Journal of Medicine. 2015;372(9):793-795. PMID:25635347. DOI: 10.1056/NEJMp1500523

    [4] Miller CW, Aslo A, Won A, Tan M, Lampkin B, Koeffler HP. Alterations of the p53, Rb and MDM2 Genes in Osteosarcoma. Journal of Cancer Research and Clinical Oncology. 1996;122(9):559-565. PMID:8781571

    [5] Miller CW, Aslo A, Campbell MJ, Kawamata N, Lampkin BC, Koeffler HP. Alterations of the p15, p16, and p18 Genes in Osteosarcoma. Cancer Genetics and Cytogenetics. 1996;86 (2):136-142. PMID:8603340

    [6] Chen X, Bahrami A, Pappo A, Easton J, Dalton J, Hedlund E, Ellison D, Shurtleff S, Wu G, Wei L, Parker M, Rusch M, Nagahawatte P, Wu J, Mao S, Boggs K, Mulder H, Yergeau D, Lu C, Ding L, Edmonson M, Qu C, Wang J, Li Y, Navid F, Daw NC, Mardis ER, Wilson RK, Downing JR, Zhang J, Dyer MA. St. Jude Children's Research Hospital-Washington University Pediatric Cancer Genome Project. Recurrent Somatic Structural Variations Contribute to Tumorigenesis in Pediatric Osteosarcoma. Cell Rep. 2014;7(1):104-112. PMID:24703847; PMCID:PMC4096827. DOI: 10.1016/j.celrep.2014.03.003

    [7] Perry JA, Kiezun A, Tonzi P, Van Allen EM, Carter SL, Baca SC, Cowley GS, Bhatt AS, Rheinbay E, Pedamallu CS, Helman E, Taylor-Weiner A, McKenna A, DeLuca DS,

    [10] Demetri GD, Chawla SP, Ray-Coquard I, Le Cesne A, Staddon AP, Milhem MM, Penel N, Riedel RF, Bui-Nguyen B, Cranmer LD, Reichardt P, Bompas E, Alcindor T, Rushing D, Song Y, Lee RM, Ebbinghaus S, Eid JE, Loewy JW, Haluska FG, Dodion PF, Blay JY. Results of an International Randomized Phase III Trial of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus Versus Placebo to Control Metastatic Sarcomas in Patients after Benefit from Prior Chemotherapy. J Clin Oncol. 2013;31(19):2485-2492. PMID:23715582. DOI: 10.1200/JCO.2012.45.5766

    [11] Sampson VP, Yoo S, Kumar A, Vetter NS, Kolb EA. MicroRNAs and Potential Targets in Osteosarcoma: Review. Front Pediatr. 2015;3:69. PMID:26380245; PMCID:PMC4547013. DOI: 10.3389/fped.2015.00069

    [12] Wan-Ibrahim WI, Singh VA, Hashim OH, Abdul-Rahman PS. Biomarkers for Bone Tumours: Discovery from Genomics and Proteomics Studies and Their Challenges. Mol Med. 2015. PMID:26581086; PMCID:PMC4818258. DOI: 10.2119/molmed.2015.00183

  • Related Research Results (1)
  • Metrics
Share - Bookmark

  • Download from
    InTech via InTech (Part of book or chapter of book, 2017)
  • Cite this publication